353 related articles for article (PubMed ID: 38111536)
1. Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.
Zhang Y; Liang L; Li Z; Huang Y; Jiang M; Zou B; Xu Y
Front Oncol; 2023; 13():1295579. PubMed ID: 38111536
[TBL] [Abstract][Full Text] [Related]
2. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
Löser DA; Shibata A; Shibata AK; Woodbine LJ; Jeggo PA; Chalmers AJ
Mol Cancer Ther; 2010 Jun; 9(6):1775-87. PubMed ID: 20530711
[TBL] [Abstract][Full Text] [Related]
3. [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
Pernin V; Mégnin-Chanet F; Pennaneach V; Fourquet A; Kirova Y; Hall J
Cancer Radiother; 2014 Dec; 18(8):790-8; quiz 799-802. PubMed ID: 25441760
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour and radiosensitising effects of PARP inhibitor on cervical cancer xenografts.
Xue Q; Enyang W; Tingting G; Xiaolin M; Qipeng M; Song G
J Obstet Gynaecol; 2023 Dec; 43(1):2171783. PubMed ID: 36786286
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors combined with radiotherapy: are we ready?
Sun C; Chu A; Song R; Liu S; Chai T; Wang X; Liu Z
Front Pharmacol; 2023; 14():1234973. PubMed ID: 37954854
[TBL] [Abstract][Full Text] [Related]
6. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
7. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.
Seo Y; Tamari K; Takahashi Y; Minami K; Tatekawa S; Isohashi F; Suzuki O; Akino Y; Ogawa K
Int J Radiat Biol; 2022; 98(7):1222-1234. PubMed ID: 34919022
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
9. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
Chalmers AJ; Lakshman M; Chan N; Bristow RG
Semin Radiat Oncol; 2010 Oct; 20(4):274-81. PubMed ID: 20832020
[TBL] [Abstract][Full Text] [Related]
11. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.
Rose M; Burgess JT; O'Byrne K; Richard DJ; Bolderson E
Front Cell Dev Biol; 2020; 8():564601. PubMed ID: 33015058
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in cancer therapy using PARP inhibitors.
Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
[TBL] [Abstract][Full Text] [Related]
13. PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities.
Li WH; Wang F; Song GY; Yu QH; Du RP; Xu P
Front Pharmacol; 2023; 14():1198948. PubMed ID: 37351512
[No Abstract] [Full Text] [Related]
14. Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation.
Hirai T; Shirai H; Fujimori H; Okayasu R; Sasai K; Masutani M
Cancer Sci; 2012 Jun; 103(6):1045-50. PubMed ID: 22404155
[TBL] [Abstract][Full Text] [Related]
15. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
van Vuurden DG; Hulleman E; Meijer OL; Wedekind LE; Kool M; Witt H; Vandertop PW; Würdinger T; Noske DP; Kaspers GJ; Cloos J
Oncotarget; 2011 Dec; 2(12):984-96. PubMed ID: 22184287
[TBL] [Abstract][Full Text] [Related]
17. NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.
Hunter JE; Willmore E; Irving JA; Hostomsky Z; Veuger SJ; Durkacz BW
Oncogene; 2012 Jan; 31(2):251-64. PubMed ID: 21706052
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitor combinations in prostate cancer.
Pezaro C
Ther Adv Med Oncol; 2020; 12():1758835919897537. PubMed ID: 32215055
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) polymerase inhibition: past, present and future.
Curtin NJ; Szabo C
Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
